Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

被引：0

作者：

Magee, Gray ^{[1
,2
]}

Mansour, Razan ^{[2
,3
]}

Chang, Mark ^{[1
,2
]}

Atrash, Shebli ^{[2
,4
]}

Ahmed, Nausheen ^{[2
,5
]}

Mushtaq, Muhammad Umair ^{[2
,6
]}

Ouchveridze, Evguenia ^{[2
,7
]}

Abdallah, Al-Ola ^{[2
,5
]}

Paul, Barry ^{[2
,4
]}

Green, Kimberly M. ^{[2
,8
]}

Davis, James A. ^{[2
,8
]}

Hashmi, Hamza ^{[2
,9
]}

机构：

[1] Atrium Hlth, Levine Canc, Charlotte, NC 28207 USA

[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA

[3] Univ Kansas Med Ctr, Internal Med, Kansas City, KS USA

[4] Wake Forest Univ, Bowman Gray Sch Med, Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[5] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA

[6] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Overland Pk, KS USA

[7] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[8] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA

[9] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

来源：

关键词：

D O I：

10.1182/blood-2024-208085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7034 / 7035

页数：2